Fabrice Chouraqui, CEO of Cellarity and Flagship Pioneering CEO-Partner, and Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub, join Paul Biondi, Flagship Executive Partner and President of Pioneering Medicines, for a discussion about the recently announced research collaboration between the three companies to unlock a new therapy for Metabolic Steatohepatitis (MASH), for which there are no currently approved treatments. More from Flagship @ JPM2024 here.
Related Companies
- Cellarity Founded: 2017
